一个治疗机构筹集1 000万美元,用于研制非致瘾性止痛药物,避免阿片类药物的风险。 SiteOne Therapeutics raises $100M to develop non-addictive pain medications, avoiding opioid risks.

San Francisco以旧金山为基础的生物技术网站“一个治疗疗法”筹集了1亿美元,用于开发非类阿片止痛药物。 San Francisco-based biotech SiteOne Therapeutics has raised $100 million to develop non-opioid pain medications. 资金由Novo Holdings领导, 将支持其离子通道调节器的临床试验, 针对慢性疼痛和等感官过度刺激障碍. The funding, led by Novo Holdings, will support clinical trials for their ion channel modulators, targeting sensory hyperexcitability disorders like chronic pain and itch. 该公司旨在通过侧重于外围神经系统,避免类阿片药物的副作用和成瘾风险。 The company aims to avoid the side effects and addiction risks of opioid drugs by focusing on the peripheral nervous system. 已增加新的董事会成员和一位执行主席,以指导公司的增长。 New board members and an executive chairperson have been added to guide the company's growth.